NEW YORK (TheStreet) -- Robert Reich, former Labor Secretary, implored the Federal Reserve not to reduce its economic stimulus program that has fueled the stock market's rise and bolstered the economic recovery since the 2008 financial crisis.
Reich, in an interview with TheStreet in New York said he opposes so-called tapering of asset purchases, arguing that unemployment remains too high and the economy remains too fragile.
"I wouldn't start tapering now; I think unemployment is still too high, I think the economy is too fragile, economic growth is still too slow -- I would wait," Reich said. "I think eventually, obviously, you have to taper, you can't continue to buy $85 billion worth of long term bonds forever.
Top 5 Services Stocks To Watch Right Now: Salix Pharmaceuticals Ltd (SLXP)
Salix Pharmaceuticals, Ltd., incorporated on December 31, 2001, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�� products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.
Xifaxan (rifaximin) tablets
Xifaxan is a gastrointestinal-specific oral antibiotic. The Food and Drug Administration ( FDA) approved Xifaxan 200 milligram for the treatment of patients 12 years of age and older with travelers��diarrhea caused by noninvasive strains of E coli. Xifaxan 550 milligram was approved by the FDA for reduction in risk of overt hepatic encephalopathy (HE), recurrence in patients 18 years of age or older.
It launched Xifaxan 200milligram in the United States and Xifaxan 550 milligram using its own direct sales force. The Company is exploring potential additional indications, formulations, clinical trials and co-promotion arrangements to capitalize on the potential for Xifaxan, including its development program in irritable bowel syndrome.
In October 2012, the USPTO declared an interference action to determine the priority of invention between Cipla�� application related to amorphous rifaximin and Solmag SpA�� application directed to amorphous rifaximin. In February 2012, the FDA posted draft bioequivalence guidance for rifaximin 550 milligram tablets. The draft guidance for rifaximin 550 milligram tablets recommends that in addition to conducting the program outlined in the FDA posted ! draft guidance document for rifaximin 200 milligram tablets discussed above, a single-dose, three-way crossover in-vivo study of fasting bioequivalence with pharmacokinetic endpoints in both fasting and fed states be performed in the 550 milligram tablets. Additionally, the guidance stipulated that the formulation of the 550 milligram strength should be proportionally similar to that of the 200 milligram strength in order to file an ANDA for approval of a generic rifaximin 550 milligram tablet for the treatment of hepatic encephalopathy.
MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid) oral solution
MoviPrep is a patent-protected, liquid polyethylene glycol-salt, or PEG, bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations.
Apriso (mesalamine) extended-release capsules 0.375 gram
Apriso is a locally-acting aminosalicylate and is the only delayed and extended release mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product�� prolonged release mechanism might allow them to expand the range of treatment options for ulcerative colitis.
Relistor (methylnaltrexone bromide)
Relistor Subcutaneous Injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved for use in over 55 countries worldwide.
OsmoPrep and Visicol (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) tablets
Visicol and OsmoPrep tablets are indicated for clean! sing of t! he colon as a preparation for colonoscopy in adults 18 years of age or older. Visicol and OsmoPrep are the only, tablet bowel cleansing products approved by the FDA and marketed in the United States. OsmoPrep is a patented, second-generation tablet bowel cleansing product that the FDA approved. OsmoPrep offers potential benefits compared to Visico,l such as its lack of microcrystalline cellulose, smaller tablet size and possible lower dose administration.
Solesta
Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for surgery or anesthesia.
Deflux
Deflux is a medical device indicated for children affected by Grades II-IV vesicoureteral reflux, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. Deflux was granted premarket approval application (PMA) approval, and has been on the market in the United States.
Fulyzaq (crofelemer) delayed-release tablets
On December 31, 2012, the FDA granted marketing approval for this product, under the trade name Fulyzaq. Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration.
Giazo (balsalazide disodium) tablets
February 3, 2012, the FDA granted marketing approval for this product under the trade name Giazo. Giazo is indicated for the treatment of mildly to moderately active ulcerative col! itis in m! ale patients 18 years of age and older. It shipped Giazo to wholesalers in 2012.
Metozolv ODT (metoclopramide hydrochloride) 5 milligrams and 10 milligrams orally disintegrating tablets
METOZOLV ODT is indicated for the relief of symptomatic gastroesophageal reflux or short-term (4-12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and diabetic gastroparesis or the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis.
Azasan (azathioprine) tablets
Azasan is an FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. It launched the 75 and 100 milligrams dosage strengths of Azasan in the United States.
Anusol-HC and Proctocort (hydrocortisone) creams and suppositories
The Company acquired the right to sell Anusol-HC 2.5% (hydrocortisone USP) cream, Anusol-HC 25 milligrams (hydrocortisone acetate) rectal suppositories, Proctocort 1% (hydrocortisone USP) cream and Proctocort 30 mg (hydrocortisone acetate) rectal suppositories from King Pharmaceuticals, Inc. The two cream products are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. The two suppository products are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions.
Pepcid (famotidine) for Oral Suspension and Diuril (Chlorothiazide)
Pepcid Oral Suspension is a widely known prescription pharmaceutical product indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and gastro-esophageal reflux disease. Pepcid Oral Suspension and Diuril Oral Suspension, both liquid form! ulations ! of their solid dosage form counterparts, compete in a combined annual United States market concentrated in pediatric and hospitalized patient populations.
Colazal (balsalazide disodium) capsules
The Company launched Colazal to physicians in the United States. FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with ulcerative colitis. The pediatric use of Colazal has been granted orphan drug designation. The Office of Generic Drugs, or OGD, approved three generic balsalazide capsule products.
The Company competes with GlaxoSmithKline plc, Giuliani S.p.A., Axcan Pharma, Inc., Abbott Laboratories, Warner Chilcott plc, Shire Pharmaceuticals Group plc, Pharmacia & Upjohn, Inc., Alaven Pharmaceutical LLC, Ferring Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Cumberland Pharmaceuticals, Inc, Prometheus Laboratories, Inc., Ranbaxy Pharmaceuticals, Ferndale Laboratories, GATE Pharmaceuticals , Nycomed , Medtronic, Inc., and Cubist Pharmaceuticals, Inc.
Advisors' Opinion:- [By Garrett Cook]
Salix Pharmaceuticals (NASDAQ: SLXP) shares tumbled 3.01 percent to $133.15 after the company agreed to merge with a unit of Cosmo Pharmaceuticals SpA.
- [By Garrett Cook]
Salix Pharmaceuticals (NASDAQ: SLXP) shares shot up 12.54 percent to $138.82 as the company reported that endpoint was met in TARGET 3 study.
Shares of GoPro (NASDAQ: GPRO) got a boost, shooting up 15.19 percent to $46.71 following an announcement by the Chicago Board Options Exchange (CBOE) that it will list options for GoPro starting Monday, July 7. GoPro shares jumped 13.39% on Monday.
Top 10 Long Term Stocks To Invest In Right Now: BIOLASE Inc (BIOL)
BIOLASE, Inc., formerly BIOLASE Technology, Inc., incorporated in 1987, is a medical technology company that develops, manufactures and markets lasers, and markets and distributes dental imaging equipment and other related products designed for applications and procedures in dentistry and medicine. The Company's dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a range of dental procedures, including cosmetic and complex surgical applications in a minimally invasive manner. The Company also manufactures and sells disposable products and accessories for its laser systems. The Company's Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed. The Company also markets flexible fibers and hands pieces. For the Company's ezlase system, the Company sells tooth whitening gel kits. In April 2012, it purchased 159 Waterlase MD Turbo laser systems from Henry Schein, Inc.
The Company's Waterlase Dentistry consists of two product lines Waterlase systems and Diode systems. In July 2011, the Company introduced the Biolase DaVinci Imaging line of imaging products, which enabled the Company to offer digital diagnostic solutions to complement the minimally invasive dental treatment solutions offered by its Waterlase and Diode dental systems. The Company added the distribution of the NewTom cone beam computed tomography (CBCT), to its imaging product line. The integration of the Company's laser products with imaging offers dental professionals the Total Technology Solution, which provides imaging capabilities for early diagnosis and minimally invasive treatment with its Waterlase iPlus and iLase laser technologies.
The Company's all-tissueWaterlase dental laser systems consist of the Waterlase iPlus, the Waterlase MD Turbo, and the Waterlase MDX 300 and 450, both introduced in February 2012. Each of these systems is designed around the Company's yttrium scandi! um gallium garnet (YSGG) laser technology that refers to the laser crystal used in the Waterlase system, which contains the elements erbium, chromium and yttrium, scandium, gallium and garnet. This crystal laser produces energy with specific absorption and tissue interaction characteristics optimized for dental applications. HydroPhotonics refers to the interaction of YSGG lasers with water to produce energy to cut tissue. It is minimally invasive and can cut hard tissue, such as bone and teeth, and soft tissue, such as gums or skin, without the heat, vibration, or pressure associated with traditional dental treatments. By eliminating heat, vibration, and pressure, the Company's Waterlase systems eliminate the need for anesthesia.
The Waterlase systems incorporate an ergonomic handpiece and a control panel located on the front of the system with precise preset functionality to control the mix of laser energy, air, and water, as well as the pulse rate. The Waterlase iPlus incorporates the iLase wireless diode laser that can be utilized for unexpected soft-tissue cases in an adjacent treatment room, controlling bleeding, and temporary pain relief.
The Company's Diode laser systems in dentistry consist of the ezlase and iLase, semiconductor diode lasers to perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and temporary pain relief. The Company's ezlase system serves the markets of general, cosmetic, orthodontic and hygienic procedures. It features a pulse mode, ComfortPulse, which allows the tissue to cool between pulses and reduces the need for anesthesia for many common procedures. Other features include a wireless foot pedal control, disposable single-use tips, color touch screen activation with up to fifteen procedure based pre-sets, a whitening hand piece, a rechargeable battery pack, and a wall mount.
The Company's imaging systems include the Company's design and distribution of extra-oral and intra-oral dental digital imaging devices. The Co! mpany's e! xpansion into digital imaging systems enables the Company to offer diagnostic solutions to complement the minimally invasive dental treatment solutions offered by the Company's Waterlase and Diode dental systems. The Company provides both high-precision intuitive diagnosis and treatment planning solutions. The Company's Biolase DaVinci Imaging systems include the D3D, a three dimensional (3D) CBCT, and portable digital x-ray and intra-oral camera devices.
The NewTom VGi is a small-footprint CBCT system that offers medical grade imaging technology. In addition to producing up to image resolution with medical grade rotating anode technology, SafeBeam technology automatically adjusts radiation dosage. The Company's Medical systems include the Diolase 10 Diode Laser. As of December 31, 2011, the Company has sold approximately 8,700 Waterlase systems, including over 4,700 Waterlase MD and iPlus systems, and more than 19,000 laser systems in total in over 60 countries. As of decembe31, 2011, the Company�� other products under development address ophthalmology, dermatology, orthopedics, podiatry, and other medical and consumer markets.
The Company competes with Lares Dental Research, Fotona d.d., KaVo Dental GmbH, Lambda SpA, J Morita Manufacturing Corp., Syneron Medical Ltd, Deka Laser Technologies, Inc. Ivoclar Vivadent, Inc., Dentsply, Inc., Royal Philips Electronics and Sirona Dental Systems, Inc.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 stock that's starting to trend within range of triggering a big breakout trade is Biolase (BIOL), which develops, manufactures and markets laser systems for dental and medical applications. This stock has been trending modestly higher in 2013, with shares up by 15.9%.
If you take a look at the chart for Biolase, you'll notice that this stock has been uptrending strong for the last month and change, with shares pushing higher from its low of $1.47 to its recent high of $2.25 a share. During that uptrend, shares of BIOL have been mostly making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of BIOL within range of triggering a big breakout trade.
Traders should now look for long-biased trades in BIOL if it manages to break out above some near-term overhead resistance levels at $2.25 to $2.50 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 311,533 shares. If that breakout hits soon, then BIOL will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $3.07 a share to $3.50 or $3.70 a share.
Traders can look to buy BIOL off weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $1.85 a share. One can also buy BIOL off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Roberto Pedone]
One health care player that's starting to trend within range of triggering a major breakout trade is Biolase (BIOL), which is a medical technology company that develops, manufactures and markets laser systems for dental and medical applications. This stock is off to a decent start in 2013, with shares up 12%.
If you take a look at the chart for Biolase, you'll notice that this stock has been trending sideways and consolidating for the last two months, with shares moving between $1.64 on the downside and $2.24 on the upside. Shares of BIOL have now started to spike higher right off its 200-day moving average of $1.87 a share. That spike is quickly pushing shares of BIOL within range of triggering a major breakout trade above the upper-end of its recent sideways trading chart pattern.
Traders should now look for long-biased trades in BIOL if it manages to break out above some near-term overhead resistance levels at $2.15 to $2.24 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 627,655 shares. If that breakout triggers soon, then BIOL will set up to re-test or possibly take out its next major overhead resistance levels at $3.50 to $4 a share.
Traders can look to buy BIOL off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $1.85 to $1.80 a share. One can also buy BIOL off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By James E. Brumley]
Looking for a quick, high-odds bullish trade? Then look for further than BIOLASE Inc. (NASDAQ:BIOL). This small medical equipment company has had nothing less than a miserable 2013, falling from a peak above $6.00 in April to a multi-year low of $1.16 on Wednesday. But, the size and scope of that plunge from BIOL has also dropped all the tell-tale hints that a rebound is nigh.
- [By Anna Prior]
Biolase Inc.(BIOL) swung to a fourth quarter loss as the dental lasers manufacturer and distributor’s revenue fell, and the company said it was exploring strategic alternatives. Revenue fell short of analysts’ expectations. Shares dropped 7.7% to $2.98 in light premarket trading.
Top 10 Long Term Stocks To Invest In Right Now: Fresh Del Monte Produce Inc.(FDP)
Fresh Del Monte Produce Inc., through its subsidiaries, produces, transports, sources, markets, and distributes fresh and fresh-cut fruit and vegetables worldwide. It also offers prepared fruit and vegetables, juices, beverages, snacks, and poultry and meat products. The company provides various fresh-cut fruit products, such as bananas, pineapples, melons, tomatoes, grapes, apples, pears, peaches, plums, nectarines, cherries, citrus, avocados, blueberries, kiwi, strawberries, plantains, mangos, and fruit cocktail; and fresh-cut vegetable products primarily consisting of potatoes, onions, bell peppers, and cucumbers, as well as prepared salads, such as coleslaw and potato salad. In addition, Fresh Del Monte Produce engages in ocean freight; and manufacture of plastics and box products comprising bins, trays, bags, and boxes. It offers fresh produce under the DEL MONTE, UTC, and Rosy brands; and prepared fruits and vegetables, juices, beverages, and snacks under the DEL MON TE, Fruit Express, Just Juice, and Fruitini brands. The company markets and distributes its products to retail stores, food clubs, wholesalers, distributors, and foodservice operators. Fresh Del Monte Produce Inc. was founded in 1886 and is based in George Town, Cayman Islands.
Advisors' Opinion:- [By Jake L'Ecuyer]
Top decliners in the sector included Fresh Del Monte Produce (NYSE: FDP), off 8.8%, and Coca-Cola Company (NYSE: KO), down 3.5%. Shares of Fresh Del Monte tumbled after the company reported weak quarterly earnings.
- [By Rich Duprey]
Slipped on a banana peel
Maybe they were just envious of rival Fresh Del Monte Produce (NYSE: FDP ) , which had served up a buyback plan the week before they did and wanted to show they had the financial wherewithal, too.� - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Fresh Del Monte Produce (NYSE: FDP ) , whose recent revenue and earnings are plotted below. - [By Jon C. Ogg]
The first list of 24/7 Wall St. stocks under book value for the month of August are Apache Corp. (NYSE: APA), Fresh Del Monte Produce Inc. (NYSE: FDP), Genworth Financial Inc. (NYSE: GNW), Ingram Micro Inc. (NYSE: IM) and JetBlue Airways Corp. (NASDAQ: JBLU). We generally have�focused on net asset values and tangible book values, as well as forward price-to-earnings multiples, share price performance, analyst expectations via the Thomson Reuters consensus price target and more.
Top 10 Long Term Stocks To Invest In Right Now: Mechel Steel Group OAO (MTL)
Mechel OAO, together with its subsidiaries, engages in mining and steel businesses in the Russian Federation, other CIS countries, Europe, Asia, the Middle East, the United States, and internationally. The company operates through four segments: Mining, Steel, Ferroalloys, and Power. The Mining segment engages in the production and sale of metallurgical and steam coal, coke, iron ore, and limestone, as well as chemical products, such as coal tar, naphthalene, and other compounds. The Steel segment produces and sells semi-finished steel products, carbon and special long products, and carbon and stainless flat products, as well as metal products, including wire products, forgings, and stampings. The Ferroalloys segment is involved in the production and sale of nickel ore, low-ferrous ferronickel, ferrochrome, and ferrosilicon. The Power segment engages in the generation and sale of electricity and heat energy from steam coal; and power distribution activities. The company, f ormerly known as Mechel Steel Group OAO, was founded in 2003 and is based in Moscow, the Russian Federation.
Advisors' Opinion:- [By Travis Hoium]
What: Shares of Russian coal miner Mechel (NYSE: MTL ) fell as much as 10% today after the company announced fiscal-fourth-quarter earnings.
- [By Lisa Levin]
Mechel OAO (NYSE: MTL) shares reached a new 52-week low of $1.57. Mechel's trailing-twelve-month revenue is $120.84 million.
Posted-In: 52-Week LowsNews Movers & Shakers Intraday Update Markets
Top 10 Long Term Stocks To Invest In Right Now: Brookfield Residential Properties Inc (BRP)
Brookfield Residential Properties Inc. (Brookfield Residential) is a land developer and homebuilder.The Company entitles and develops land and builds homes for its own communities, as well as sells lots to third-party builders. It operates in three segments in North America: Canada, California and Central and Eastern U.S. Each of the Company�� segments specializes in lot entitlement and development and the construction of single-family and multi-family homes. As of December 31, 2011, Brookfield Residential controlled 108,197 lots. The Company became a public company on March 31, 2011, by combining the former business of Brookfield Homes Corporation (Brookfield Homes) and the residential land and housing division (BPO Residential) of Brookfield Office Properties Inc. into a single residential land and housing company, achieved through a merger and series of related transactions completed on March 31, 2011. Advisors' Opinion:- [By Garrett Cook]
Brookfield Residential Properties (NYSE: BRP) shares shot up 21.51 percent to $23.10 after Brookfield Asset Management (NYSE: BAM) proposed to acquire around 30% of the company not currently owned for $23 per share.
Top 10 Long Term Stocks To Invest In Right Now: SLM Corporation(SLM)
SLM Corporation, through its subsidiaries, originates, acquires, finances, and services private education loans in the United States. It offers processing capabilities to educational institutions, 529 college-savings plan program management services, and a consumer savings network. The company also provides servicing, loan default aversion, and defaulted loan collection services for loans owned by the Department of Education (ED), Guarantors of FFELP Loans, and other institutions. In addition, SLM Corporation offers campus solutions, which comprise electronic billing, collection, payment and refund, and tuition payment plan administration services. The company promotes its products through the financial aid offices on campuses, as well as through direct marketing to students and their families. SLM Corporation was founded in 1972 and is headquartered in Newark, Delaware.
Advisors' Opinion:- [By Rich Duprey]
Private student loan provider�Sallie Mae� (NASDAQ: SLM ) �announced yesterday�its third-quarter dividend of $0.87125�per share on its Series A preferred stock.
- [By Sean Williams]
What: Shares of SLM Corp (NASDAQ: SLM ) , better known as Sallie Mae, jumped as much as 14% after announcing a new CEO and unveiling strategic plans to split into two separate companies. Shares have since given back much of their gains and are now up just 4% as of this writing.
- [By Jay Jenkins]
SLM (NASDAQ: SLM ) , the nation's largest non-government student loan lender, is considering splitting itself into two entities via an IPO later this year. But a private buyer might get to Sallie Mae first.
- [By Dan Caplinger]
Gerald Herber/AP Student loans have become an increasingly large portion of the debt burden that Americans face. During the past six years, consumers have paid down their outstanding balances on most forms of debt, including mortgages, credit cards and auto loans, according to the New York Federal Reserve. But student loan balances have continued to increase. The Consumer Financial Protection Bureau noted earlier this year that outstanding student debt would shortly hit the $1.2 trillion mark. Most of the loans that students take are federal government loans, with various features that can include subsidies for interest payments while you're in school, fixed interest rates throughout the life of your loan, and opportunities for deferments, forbearance, and even outright loan forgiveness under certain circumstances. But even though private student loans represent a small portion of the overall loan market -- about 14 percent, according to figures from the CFPB -- the lenders that offer private loans have gotten a number of complaints from borrowers citing various problems. Let's take a look at the CFPB report that goes through types of trouble borrowers have had recently with their student lenders to find some key conclusions. 1. Lenders Want Your Business. For the most part, few borrowers cited any problems with actually a private student loan. Just 4 percent of the complaints to the CFPB had to do with obtaining loans, strongly suggesting that most of those who need financing aren't having banks turn them away. Lenders have good reasons to prefer student loans. Unlike most other forms of debt, student loans give creditors protection against discharge in bankruptcy, meaning that borrowers often have to repay their student debt even if they go bankrupt and have other debts wiped out. 2. Competition Is Limited. Looking at which lenders got the most complaints, Sallie Mae (SLM) was the winner by far, with nearly 800 complaints representing almost 40 percent
Top 10 Long Term Stocks To Invest In Right Now: Metro Bancorp Inc(METR)
Metro Bancorp, Inc. operates as the bank holding company for Metro Bank, which provides a range of retail and commercial banking services to consumers and small and mid-sized companies in Pennsylvania. Its deposit products include personal and business checking accounts, regular savings accounts, money market accounts, interest checking accounts, fixed rate certificates of deposit, individual retirement accounts, and club accounts. The company?s loan products portfolio comprises commercial and industrial, owner occupied real estate, commercial construction and land development, and commercial real estate loans; consumer loans, including home equity, overdraft checking protection, and consumer credit cards, as well as installment loans for home improvement, and the purchase of consumer goods and automobiles; and construction loans and permanent mortgages for homes. It also offers debit card services, online banking services, safe deposit facilities, and automated teller fa cilities. As of July 14, 2011, Metro Bancorp operated 33 stores in the counties of Berks, Cumberland, Dauphin, Lancaster, Lebanon, and York. The company was formerly known as Pennsylvania Commerce Bancorp, Inc. and changed its name to Metro Bancorp, Inc. in June 2009. Metro Bancorp, Inc. was founded in 1984 and is headquartered in Harrisburg, Pennsylvania.
Advisors' Opinion:- [By Tim Melvin]
Metro Bancorp (METR) is one bank that might consider selling based on these metric. The company�� return on assets has consistently been well below its peer group, and the equity-to-asset ratio is just 8.46 — well below the 11 average across the United States.
No comments:
Post a Comment